Application of immunotherapy in advanced non-small cell lung cancer with hypertension: a multicenter retrospective analysis
The non-hypertensive group was associated with a lower risk of mortality than hypertensive group. In subgroup analysis, no baseline indicator was observed a significant correlation with survival prognosis on OS and PFS in hypertensive patients. Our findings provided an important prognostic factor to improve the prognosis of advanced NSCLC patients receiving immunotherapy. Prospective randomized trials are needed to further validate these findings.
Authors
- Jiadi Gan (ORCID: https://orcid.org/0009-0005-1199-7656)
- Kin Fong Lei (ORCID: https://orcid.org/0000-0002-5356-2221)
- Bojiang Chen (ORCID: https://orcid.org/0000-0002-4882-9817)
- Juan Wang (ORCID: https://orcid.org/0000-0001-7312-4723)
- Xiaoting Gu (ORCID: https://orcid.org/0000-0001-5832-2078)
- Quanling Kong
- Tao Chang
- Li-na He
- Jingyi Yuan (ORCID: https://orcid.org/0000-0002-2850-1582)
Institutions
- Qingdao University (CN)
- Sun Yat-sen University (CN)
- Jilin University (CN)
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Affiliated Hospital of Qingdao University (CN)
- First Hospital of Jilin University (CN)
- Sun Yat-sen University Cancer Center (CN)
- Ministry of Education (KN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-09-12
- DOI
- https://doi.org/10.3389/fonc.2025.1621363
- Citations
- 1
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52